Blueprint Medicines Corp at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Good morning, everyone. Thanks for joining us. I'm Salveen Richter, Biotechnology Analyst at Goldman Sachs, and we're really pleased to have Blueprint with us. From the company, we have Jeff Albers, CEO; and Fouad Namouni, President of R&D.
Questions & Answers
With that, to start, Jeff, maybe you could talk about your ex U.S. footprint in the recent collaborations with Roche, what is strategy for other assets and partnerships and leveraging the existing infrastructure?
Sure. First of, Salveen, thanks for including us. And on behalf of the employees of Blueprint Medicines, I want to thank you and the Goldman Sachs team.
Obviously, we will be making forward-looking statements, so disclaim any obligation to update those and would refer people to our
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
